Published in Lab Law Weekly, January 12th, 2007
The company reached an agreement last month with Bioniche Pharma Holdings Limited and the shareholders of that company to sell its 10% ownership position in Bioniche Pharma Holdings and its annual royalty payments for each of the next 5 years related to sales of Suplasyn for a total of US$6 million. Suplasyn is a proprietary product for the treatment of osteoarthritis in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.